Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173342 | 1.00 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL6923711 | 0.91 | BACE1 (0.84) | BACE1APP | |
| SCHEMBL362245 | 0.90 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL361455 | 0.89 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL370707 | 0.89 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL369802 | 0.89 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL362660 | 0.89 | BACE1 (1.00) | BACE1APP | |
| Hydrochloric Acid SCHEMBL361775 | 0.89 | BACE1 (0.98) | BACE1APP | |
| SCHEMBL362891 | 0.88 | BACE1 (0.84) | BACE1APP | |
| SCHEMBL362026 | 0.88 | BACE1 (1.00) | BACE1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011020806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-24 | — | — | WO | claimed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | claimed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | claimed |
| US-9828350-B2 | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-28 | — | — | US | disclosed |
| US-9828350-B2 | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-28 | — | — | US | disclosed |
| EP-2580200-B1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2016-06-02 | — | — | US | disclosed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | disclosed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | disclosed |
| WO-2011154431-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011020806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885APP 4/4885 |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | BACE1 69/4885APP 94/4885 |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | BACE1 2/4885APP 3/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | BACE1 69/4885APP 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.